TY - JOUR
T1 - Correlations between serotonin impairments and clinical indices in multiple system atrophy
AU - Nagao, Ryunosuke
AU - Mizutani, Yasuaki
AU - Shima, Sayuri
AU - Ueda, Akihiro
AU - Ito, Mizuki
AU - Yoshimoto, Junichiro
AU - Watanabe, Hirohisa
N1 - Publisher Copyright:
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2024/3
Y1 - 2024/3
N2 - Background and purpose: Multiple system atrophy (MSA) is a neurodegenerative disease with characteristic motor and autonomic symptoms. Impaired brain serotonergic innervation can be associated with various clinical indices of MSA; however, the relationship between clinical symptoms and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA), a main serotonin metabolite, has not been fully elucidated. Methods: To compare CSF 5-HIAA levels between patients with MSA and healthy controls, we included 33 controls and 69 MSA patients with either predominant parkinsonian or cerebellar ataxia subtypes. CSF 5-HIAA levels were measured using high-performance liquid chromatography. Additionally, we investigated correlations between CSF 5-HIAA and various clinical indices in 34 MSA patients. Results: CSF 5-HIAA levels were significantly lower in MSA patients than in controls (p < 0.0001). Probable MSA patients had lower CSF 5-HIAA levels than possible MSA patients (p < 0.001). In MSA patients, CSF 5-HIAA levels were inversely correlated with scores in Parts 1, 2, and 4 of the Unified Multiple System Atrophy Rating Scale, and with systolic and diastolic blood pressure in Part 3. Structural equation modeling revealed significant paths between serotonin and clinical symptoms, and significance was highest for activities of daily living, walking, and body sway. Conclusions: Serotonin dysfunction, as assessed by CSF 5-HIAA levels, may implicate greater MSA severity.
AB - Background and purpose: Multiple system atrophy (MSA) is a neurodegenerative disease with characteristic motor and autonomic symptoms. Impaired brain serotonergic innervation can be associated with various clinical indices of MSA; however, the relationship between clinical symptoms and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA), a main serotonin metabolite, has not been fully elucidated. Methods: To compare CSF 5-HIAA levels between patients with MSA and healthy controls, we included 33 controls and 69 MSA patients with either predominant parkinsonian or cerebellar ataxia subtypes. CSF 5-HIAA levels were measured using high-performance liquid chromatography. Additionally, we investigated correlations between CSF 5-HIAA and various clinical indices in 34 MSA patients. Results: CSF 5-HIAA levels were significantly lower in MSA patients than in controls (p < 0.0001). Probable MSA patients had lower CSF 5-HIAA levels than possible MSA patients (p < 0.001). In MSA patients, CSF 5-HIAA levels were inversely correlated with scores in Parts 1, 2, and 4 of the Unified Multiple System Atrophy Rating Scale, and with systolic and diastolic blood pressure in Part 3. Structural equation modeling revealed significant paths between serotonin and clinical symptoms, and significance was highest for activities of daily living, walking, and body sway. Conclusions: Serotonin dysfunction, as assessed by CSF 5-HIAA levels, may implicate greater MSA severity.
KW - 5-hydroxyindoleacetic acid
KW - cerebrospinal fluid
KW - disease severity
KW - multiple system atrophy
KW - serotonergic neurons
UR - http://www.scopus.com/inward/record.url?scp=85179322289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179322289&partnerID=8YFLogxK
U2 - 10.1111/ene.16158
DO - 10.1111/ene.16158
M3 - Article
AN - SCOPUS:85179322289
SN - 1351-5101
VL - 31
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 3
M1 - e16158
ER -